Gastroenterology
Volume 119, Issue 6 , Pages 1631-1636 , December 2000

Epidemiology and natural history of primary biliary cirrhosis in a U.S. community

Received 8 November 1999 ,Accepted 12 July 2000.

References 

  1. Kaplan MM. Primary biliary cirrhosis. N Engl J Med. 1996;335:1570–1580
  2. Neuberger J. Primary biliary cirrhosis. Lancet. 1997;350:875–879
  3. Myszor M. OFW James The epidemiology of primary biliary cirrhosis in the northeast of England: an increasingly common disease?. Q J Med. 1990;75:377–385
  4. Löfgren J, Järnerot D, Danielsson D, Hemdal I. Incidence and prevalence of primary biliary cirrhosis in a defined population in Sweden. Scand J Gastroenterol. 1985;20:647–650
  5. Danielsson A, Boqvist L, Uddenfeldt P. Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. Hepatology. 1990;11:458–464
  6. Hamlyn AN, Macklon AF, James OFW. Primary biliary cirrhosis: geographical clustering and symptomatic onset seasonality. Gut. 1983;24:940–945
  7. Watson RG, Angus PW, Dewar M, Goss B, Sewell RM, Smallwood RA. Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group. Gut. 1995;36:927–930
  8. Witt-Sullivan H, Heathcote J, Cauch K, et al.  The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology. 1990;23:98–105
  9. Triger DR, Berg PA, Rodes J. Epidemiology of primary biliary cirrhosis. Liver. 1984;4:195–200
  10. Remmel T, Remmel H, Uibo R, Salupere V. Primary biliary cirrhosis in Estonia. With special reference to incidence, prevalence, clinical features, and outcome. Scand J Gastroenterol. 1995;30:367–371
  11. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33:99–103
  12. Eriksson S, Lindgren S. The prevalence and clinical spectrum of primary biliary cirrhosis in a defined population. Scan J Gastroenterol. 1984;19:971–976
  13. Goudie BM, MacFarlane G, Boyle P, Burt AD, Gillis CR, MacSween RNM, et al. Epidemiology of antimitochondrial antibody seropositivity and primary biliary cirrhosis in the west of Scotland (abstr). Gut. 1987;28:A1346
  14. Metcalf JV, Bhopal RS, Gray J, Howel D, James OFW. Incidence and prevalence of primary biliary cirrhosis in the City of New Castle upon Tyne, England. Int J Epidemiol. 1997;26:830–836
  15. James OFW, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JB. Primary biliary cirrhosis once rare, now common in the United Kingdom?. Hepatology. 1999;30:390–394
  16. Kim WR, Dickson ER. Predictive model of natural history of cholestatic liver disease. Clin Liver Dis North Am. 1998;2:313–332
  17. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 1989;10:1–7
  18. Grambsch PM, Dickson ER, Kaplan M, LeSage G, Fleming TR, Langworthy AL. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology. 1989;10:846–850
  19. Klion FM, Fabry TL, Palmer M, Schaffner F. Prediction of survival of patients with primary biliary cirrhosis. Gastroenterology. 1992;102:310–313
  20. Murtaugh PA, Dickson ER, Van Dam GM, Malinchoc M, Grambsch PM, Langworthy AL, et al. Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits. Hepatology. 1994;20:126–134
  21. Melton JL. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71:266–274
  22. Kurland LT, Molgaard CA. The patient record in epidemiology. Sci Am. 1981;245:54–63
  23. Bergstralh EJ, Offord KP, Chu CP, Beard CM, O'Fallon WM, Melton LJ. Calculating incidence, prevalence and mortality rates for Olmsted County, Minnesota: an update. Technical Report Series; no. 49. Rochester, MN: Mayo Clinic; 1992;
  24. McCullagh P, Nelder JA. Generalized linear models. In:  Cox DR,  Hinkley DV,  Rubin D,  Silvermann BVW editor. New York: Chapman and Hall; 1982;p. 127–147
  25. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  26. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monograph. 1961;6:101–121
  27. Therneau TM, Offord J. Expected survival based on hazard rates (update), Technical Report no. 63. Rochester, MN: Department of Health Sciences Research. : Mayo Clinic; 1999;
  28. Thomsen BL, Keiding N, Altman DG. A note on the calculation of expected survival of liver transplant patients. Stat Med. 1991;10:733–738
  29. Bach N, Schaffner F. Familial primary biliary cirrhosis. J Hepatol. 1994;20:698–701
  30. Kim WR, Poterucha JJ, Jorgensen RA, et al.  Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology. 1997;26:22–26
  31. Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF, et al. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut. 1994;35:260–265
  32. Inverizzi P, Crosignani A, Battezzati PM, Covini G, Valle GD, Larghi A, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology. 1997;25:1090–1095
  33. Doufour MC. Chronic liver disease and cirrhosis. In:  Everhart JE editors. Digestive diseases in the United States: epidemiology and impact. Washington, DC: US Government printing office; 1994;p. 619–620 US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease. NIH publication no. 94-1447
  34. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994;106:1284–1290
  35. Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med. 1994;330:1342–1347
  36. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1994;19:1149–1156
  37. Heathcote EJ, Lindor KD, Poupon R, Cauch-Dubek K, Dickson ER, Trout R, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997;113:884–890
  38. Kilmurry MR, Heathcote EJ, Cauch-Dudek K, O'Rourke K, Bailey RJ, Blendis LM, et al. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?. Hepatology. 1996;23:1148–1153

☆ Address requests for reprints to: W. Ray Kim, M.D., Division of Gastroenterology and Hepatology (Ch10), Mayo Clinic and Foundation, 200 First Street S.W., Rochester, Minnesota 55905. e-mail: kim.woong@mayo.edu; fax: (507) 266-2810.

☆☆ Supported by grants DK34238 and AR30582 from the National Institutes of Health and the Mayo Foundation for Medical Research and Education.

PII: S0016-5085(00)10403-2

Gastroenterology
Volume 119, Issue 6 , Pages 1631-1636 , December 2000

Article Tools

* Image Usage & Resolution